cor2ed
engage checkpoint medical linkedin twitter
bg

Patient case reports: from diagnosis to treatment of TRK-fusion positive cancer

Patient case reports: from diagnosis to treatment of TRK-fusion positive cancer

Dr Philipp Ivanyi, Assoc. Prof. Caterina Marchiò, Prof. David Hong

On-demand educational resources (e-learning, videos and slide site) are now available following a successful NTRK CONNECT Experts Knowledge Share event delivering practical  insights and experiences on the diagnosis and treatment of TRK fusion-positive cancer. A number of adult cancer cases were discussed including lung cancer, GI cancer, sarcoma and thyroid cancer.

 

Dr Philipp Ivanyi

Medical Oncologist

Hannover Medical School

Germany

Portrait of Caterina Marchiò
Assoc. Prof. Caterina Marchiò

Pathologist

University of Turin

Italy

Prof. David Hong

Medical Oncologist

MD Anderson Cancer Center, Houston

United States (US)

preview next

Assoc. Prof. Caterina Marchio: A lung cancer case

time E-learning | open 15 min |accreditation: EACCME | Nov 2022

This programme was made for you:   your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

Prof. David Hong: Lung cancer, sarcoma and GI cancer

time E-learning | open 15 min |accreditation: EACCME | Nov 2022

This programme was made for you:   your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

Dr Philipp Ivanyi: A thyroid cancer case

time E-learning | open 20 min |accreditation: EACCME | Nov 2022

This programme was made for you:   your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

Patient case reports: from diagnosis to treatment of TRK-fusion positive cancer

 

The key clinical takeaways from this accredited e-learning are:

  • There are a range testing approaches and diagnostic algorithms available to identify patients with TRK fusion-positive cancers
  • Practical guidance is available on how to test for NTRK fusions in many cancers including lung, sarcoma, GI and thyroid cancer
  • The two first-generation TRK inhibitors, larotrectinib and entrectinib, have demonstrated robust efficacy and safety in many cancers

 

Take the e-learning and claim your CME credit. 

This course has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) and ECMEC® is available. Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca and Bayer.

Other programmes of interest